Pharma Q2 Preview : Cipla to see steady qtr ; higher profit growth for DRL
Cipla could deliver healthy growth of 5% in the Indian business in the second quarter, but the US business is likely to witness pressure on account of lower Albuterol Sulphate sales. Revenue for the quarter is likely to grow at 13% year-on-year (YoY), according to an average estimate of three (...)
Site référencé: The Economic Times
The Economic Times
Last day to buy the shares of smallcap stock to qualify for 4:1 bonus issue as record date approaches
28/08/2025
AI giant Nvidia beats earnings expectations but shares fall
28/08/2025
Motilal Oswal Securities bullish on India's consumer sector ; HUL, Marico among top picks
28/08/2025
Silver prices hit record high of Rs 1,20,000 amid US tariff impact
28/08/2025
Ferrous metals post strong gains in Q1, non-ferrous players struggle
28/08/2025
Bankers expect little risk to credit growth, asset quality from US tariffs
27/08/2025
